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Abstract 
We report a rare presentation of a 66-year-old female with diffuse metastatic 
adenocarcinoma of unknown primary involving liver, lymphatic system and bone 
metastases. The neoplastic cells were positive for CK7 and OC125, while negative for CK20, 
thyroid transcription factor 1, CDX2, BRST-2, chromogranin, synaptophysin, estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2/neu). Fluorescence in situ hybridization showed no amplification of the HER2/neu 
gene. Molecular profiling reported a breast cancer origin with a very high confidence score 
of 98%. The absence of immunohistochemistry staining for ER, PR, and HER2/neu further 
classified her cancer as triple-negative breast cancer. Additional studies revealed high 
expression levels of topoisomerase (Topo) I, androgen receptor, and ribonucleoside-
diphosphate reductase large subunit; the results were negative for thymidylate synthase, 
Topo II-ɲ and O6-methylguanine-DNA methyltransferase. The patient was initially treated 
with a combination regimen of cisplatin and etoposide, and she experienced a rapid 
resolution of cancer-related symptoms. Unfortunately, her therapy was complicated by a 
cerebrovascular accident (CVA), which was thought to be related to cisplatin and high serum 
mucin. After recovery from the CVA, the patient was successfully treated with second-line 
chemotherapy based on her tumor expression profile. We highlight the role of molecular Case Rep Oncol 2012;5:9–16 
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profiling in the diagnosis and management of this patient and the implication of 
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